EGRX Estados financieros: Análisis de Eagle Pharmaceuticals Inc AI

Inicio

Acciones

EGRX

EGRX Financiero

Eagle Pharmaceuticals Inc

$0.25

Al cierre: Feb 13, 16:00:00 GMT-5

$0.25

Mercado Posterior: Feb 13, 20:00:00 GMT-5

Visión general Pronóstico Ganando Dividendos Finanzas

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

EGRX Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Ingresos	257	316	171	187	195	213
Crecimiento de los Ingresos (YoY)	-6%	85%	-9%	-4%	-8%	-10%
Costo de los ingresos	77	94	42	45	60	61
Utilidad bruta	179	221	129	142	135	151
Venta, General y Administración	102	85	75	78	76	60
Investigación y Desarrollo	35	34	51	30	36	44
Gastos de Operación	143	119	126	109	113	104
Otras Ingresos (Gastos) No Operativos	5	-1	0	-8	0	--
Ingreso antes de impuestos	29	61	-4	22	22	34
Gasto por Impuesto a la Renta	17	25	4	10	7	2
Ingreso Neto	12	35	-8	12	14	31
Crecimiento de la Utilidad Neta	-45%	-538%	-167%	-14%	-55%	-39%
Acciones en Circulación (Diluidas)	13.2	13.1	13.1	13.8	14.1	15.3
Cambio de Acciones (YoY)	3%	0%	-5%	-2%	-8%	-4%
EPS (Diluido)	0.91	2.73	-0.66	0.87	1.01	2.09
Crecimiento de EPS	-49%	-514%	-176%	-14%	-52%	-36%
Flujo de efectivo libre	-9	50	27	48	55	52
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	69.64%	69.93%	75.43%	75.93%	69.23%	70.89%
Margen de operación	14%	32.27%	1.16%	17.64%	10.76%	22.06%
Margen de beneficio	4.66%	11.07%	-4.67%	6.41%	7.17%	14.55%
Margen de flujo de caja libre	-3.5%	15.82%	15.78%	25.66%	28.2%	24.41%
EBITDA	56	114	5	36	25	50
Margen de EBITDA	21.78%	36.07%	2.92%	19.25%	12.82%	23.47%
D&A para EBITDA	20	12	3	3	4	3
EBIT	36	102	2	33	21	47
Margen de EBIT	14%	32.27%	1.16%	17.64%	10.76%	22.06%
Tasa de Impuesto Efectiva	58.62%	40.98%	-100%	45.45%	31.81%	5.88%

Estadísticas clave

Cierre Anterior

$0.25

Precio de apertura

$0.25

Rango del día

$0.25 - $0.25

Rango de 52 semanas

$0.1 - $3.87

Volumen

2.2K

Volumen promedio

3.7K

EPS (TTM)

0.92

Rendimiento de dividendos

Cap. de mercado

$3.2M

¿Qué es EGRX?

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.



Características

Copiloto de IA para Acciones y Criptomonedas

Predicción de precios

Seguimiento de Recaudación de Fondos

Temas

Comparación de Criptomonedas

Recursos